Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Saved in:
| Title: | Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. |
|---|---|
| Authors: | Richardson, Debra L.1,2 (AUTHOR) debra-richardson@ouhsc.edu, Moore, Kathleen N.1,2 (AUTHOR) kathleen-moore@ouhsc.edu, Vergote, Ignace3 (AUTHOR) ignace.vergote@uzleuven.be, Gilbert, Lucy4 (AUTHOR) lucy.gilbert@mcgill.ca, Martin, Lainie P.5 (AUTHOR) lainie.martin@pennmedicine.upenn.edu, Mantia-Smaldone, Gina M.6 (AUTHOR) gina.mantia-smaldone@fccc.edu, Castro, Cesar M.7 (AUTHOR) cmcastro@mgh.harvard.edu, Provencher, Diane8 (AUTHOR) diane.provencher.med@ssss.gouv.qc.ca, Matulonis, Ursula A.9 (AUTHOR) ursula_matulonis@dfci.harvard.edu, Stec, James10 (AUTHOR) james.stec@immunogen.com, Wang, Yuemei10 (AUTHOR) yuemei.wang@immunogen.com, Method, Michael10 (AUTHOR) michael.method@immunogen.com, O'Malley, David M.1,11 (AUTHOR) david.o'malley@osumc.edu |
| Source: | Gynecologic Oncology. Jun2024, Vol. 185, p186-193. 8p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 177845523 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Richardson%2C+Debra+L%2E%22">Richardson, Debra L.</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> debra-richardson@ouhsc.edu</i><br /><searchLink fieldCode="AR" term="%22Moore%2C+Kathleen+N%2E%22">Moore, Kathleen N.</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> kathleen-moore@ouhsc.edu</i><br /><searchLink fieldCode="AR" term="%22Vergote%2C+Ignace%22">Vergote, Ignace</searchLink><relatesTo>3</relatesTo> (AUTHOR)<i> ignace.vergote@uzleuven.be</i><br /><searchLink fieldCode="AR" term="%22Gilbert%2C+Lucy%22">Gilbert, Lucy</searchLink><relatesTo>4</relatesTo> (AUTHOR)<i> lucy.gilbert@mcgill.ca</i><br /><searchLink fieldCode="AR" term="%22Martin%2C+Lainie+P%2E%22">Martin, Lainie P.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<i> lainie.martin@pennmedicine.upenn.edu</i><br /><searchLink fieldCode="AR" term="%22Mantia-Smaldone%2C+Gina+M%2E%22">Mantia-Smaldone, Gina M.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<i> gina.mantia-smaldone@fccc.edu</i><br /><searchLink fieldCode="AR" term="%22Castro%2C+Cesar+M%2E%22">Castro, Cesar M.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<i> cmcastro@mgh.harvard.edu</i><br /><searchLink fieldCode="AR" term="%22Provencher%2C+Diane%22">Provencher, Diane</searchLink><relatesTo>8</relatesTo> (AUTHOR)<i> diane.provencher.med@ssss.gouv.qc.ca</i><br /><searchLink fieldCode="AR" term="%22Matulonis%2C+Ursula+A%2E%22">Matulonis, Ursula A.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<i> ursula_matulonis@dfci.harvard.edu</i><br /><searchLink fieldCode="AR" term="%22Stec%2C+James%22">Stec, James</searchLink><relatesTo>10</relatesTo> (AUTHOR)<i> james.stec@immunogen.com</i><br /><searchLink fieldCode="AR" term="%22Wang%2C+Yuemei%22">Wang, Yuemei</searchLink><relatesTo>10</relatesTo> (AUTHOR)<i> yuemei.wang@immunogen.com</i><br /><searchLink fieldCode="AR" term="%22Method%2C+Michael%22">Method, Michael</searchLink><relatesTo>10</relatesTo> (AUTHOR)<i> michael.method@immunogen.com</i><br /><searchLink fieldCode="AR" term="%22O'Malley%2C+David+M%2E%22">O'Malley, David M.</searchLink><relatesTo>1,11</relatesTo> (AUTHOR)<i> david.o'malley@osumc.edu</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Gynecologic+Oncology%22">Gynecologic Oncology</searchLink>. Jun2024, Vol. 185, p186-193. 8p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=177845523 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ygyno.2024.01.045 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 186 Titles: – TitleFull: Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Richardson, Debra L. – PersonEntity: Name: NameFull: Moore, Kathleen N. – PersonEntity: Name: NameFull: Vergote, Ignace – PersonEntity: Name: NameFull: Gilbert, Lucy – PersonEntity: Name: NameFull: Martin, Lainie P. – PersonEntity: Name: NameFull: Mantia-Smaldone, Gina M. – PersonEntity: Name: NameFull: Castro, Cesar M. – PersonEntity: Name: NameFull: Provencher, Diane – PersonEntity: Name: NameFull: Matulonis, Ursula A. – PersonEntity: Name: NameFull: Stec, James – PersonEntity: Name: NameFull: Wang, Yuemei – PersonEntity: Name: NameFull: Method, Michael – PersonEntity: Name: NameFull: O'Malley, David M. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: Jun2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 00908258 Numbering: – Type: volume Value: 185 Titles: – TitleFull: Gynecologic Oncology Type: main |
| ResultId | 1 |
